Adagene Inc ADR(ADAG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.38 | Insider Own | 18.49% | Shs Outstand | 67.1M | Perf Week | 9.84% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | -34.17% | Insider Trans | 0.38% | Shs Float | 54.7M | Perf Month | -16.25% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.28 | Inst Own | 18.73% | Short Float | 3.87% | Perf Quarter | -28.53% |
| Income | -0.02B | P/S | 19.31 | EPS this Y | -60% | Inst Trans | 40.63% | Short Ratio | 7.49 | Perf Half Y | -27.17% |
| Sales | 0.01B | P/B | 2.01 | EPS next 5Y | - | ROA | -20.55% | Short Interest | 2.12M | Perf YTD | 41.8% |
| Book/sh | 1.33 | P/C | 1.41 | EPS past 3/5Y | 41.25% 21.03% | ROE | -28.57% | 52W High | -44.74% ($4.85) | Perf Year | 45.65% |
| Cash/sh | 1.91 | P/FCF | - | Sales past 3/5Y | -6.07% 61.4% | ROIC | -19.17% | 52W Low | 106.15% ($1.30) | Perf 3Y | 97.06% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 41.48% | Gross Margin | 94.22% | Volatility(W/M) | 8.3% 9.67% | Perf 5Y | -76.16% |
| Dividend TTM | - | EV/Sales | 8.01 | Sales Y/Y TTM | 8906.15% | Oper. Margin | -240.31% | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.02 | EPS Q/Q | - | Profit Margin | -220.66% | RSI (14) | 48.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.02 | Sales Q/Q | - | SMA20 | 4.38% ($2.57) | Beta | 0.66 | Target Price | $9.74 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/12 | SMA50 | -13.07% ($3.08) | Rel Volume | 0.61 | Prev Close | $2.67 |
| Employees | 128 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -21.66% ($3.42) | Avg Volume(3M) | 0.28M | Price | $2.68 |
| IPO | 2021/2/9 | Option/Short | No/Yes | Trades | 914 | Volume | 172,575 | Change | 0.37% |
🧬 Adagene (ADAG) is a clinical-stage biotech company developing novel antibody-based immuno-oncology therapies by combining computational biology with artificial intelligence. Through its proprietary masking antibody platform, the company designs precision antibodies that are activated only in the tumor microenvironment, with improved safety and tolerability positioned as its core differentiator.
Over the past 1 year, roughly in the middle
45% below its 1-year high.
Traded less than usual. That is 61% of its average volume.
ADAG has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -60.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,931. Peers typically go for $1,089.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -76.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PGJ Invesco Golden Dragon China ETF <0.01% It ranks #310 of 594 in the industry
Based on market cap of $180M.
SION#309 Sionna Therapeutics Inc $181M PER - ADAG#310 Adagene Inc ADR $180M PER - 
UPB#311 Upstream Bio Inc $179M PER - 
MDWD#312 MediWound Ltd $179M PER - 
IVVD#313 Invivyd Inc $177M PER - 
FAQ
What kind of company is ADAG?
ADAG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ADAG?
The market cap of ADAG is approximately $180M, ranking 4,102 within its sector.
What is the 52-week high and low for ADAG?
ADAG has recorded a 52-week high of $4.85 and a low of $1.30.
